Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase II NCT06792695

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer — Recruiting • Phase II • Oncology • NCT06792695.

📅 20 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06792695
Sponsor
AstraZeneca
Start
2025-03-12
ClinicaliQ Trial Snapshot
  • A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer — Recruiting • Phase II • Oncology • NCT06792695.
  • What is being tested: Novel therapeutic interventions and their combinations for colorectal cancer treatment, with primary focus on evaluating safety profiles and clinical efficacy in this patient population.
  • Patient eligibility overview: Participants with confirmed colorectal cancer diagnosis are eligible; specific inclusion criteria regarding disease stage, prior treatment history, and performance status would be detailed in the full protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Eligibility Snapshot
  • Overall Inclusion Criteria: * Histopathologically confirmed colorectal adenocarcinoma. * Provision of FFPE tumor sample collected as per SoC. * Presence of measurable disease by RECIST 1.1 criteria. * ECOG performance status of 0 or 1. * Life expectancy ≥ 12 weeks at the time of screening. Substudy Inclusion Criteria: * No radiological evidence of liver metastasis. * No prior systemic therapy for mCRC, except for neoadjuvant/adjuvant chemotherapy where, > 6 months have elapsed between completion of therapy and documented date of diagnosis of recurrent or metastatic disease. * Known pMMR/MSS status (only pMMR/MSS mCRC allowed). * Adequate organ and bone marrow function * Body weight > 35 kg at screening and at randomization. * Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Overall

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
Teen’s death inspires mum’s drive for earlier rare cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Soft tissue sarcomas in teenagers are being diagnosed late, prompting new diagnostic guidance to improve early recognition and outcomes Parents and clinicians…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
The Irish international rugby ‘trailblazer’ and her legacy of cancer awareness
Oncology · BBC Health · 30 Sep 2026
A prominent Irish rugby player's death from breast cancer highlights the importance of raising awareness about symptoms among younger women, even in…
View brief →